FDA Approves Yeztugo: First Twice-Yearly Injection to Prevent HIV Infection

In a groundbreaking stride for global health, the U.S. Food and Drug Administration has greenlit Yeztugo, a revolutionary twice-yearly injection designed to prevent HIV infection. Developed by Gilead Sciences, this first-of-its-kind injectable, known scientifically as lenacapavir, marks a seismic shift in the fight against HIV. Unlike daily oral medications, Yeztugo offers a long-acting shield, reducing the risk of sexually acquired HIV in adults and adolescents with just two shots a year.

Clinical trials have showcased Yeztugo’s near-perfect efficacy, outperforming existing daily options like Truvada. The drug’s unique multi-stage approach disrupts HIV at various points in its lifecycle, earning it the prestigious title of 2024 Breakthrough of the Year by the journal Science. This isn’t just a medical win—it’s a beacon of hope for ending the HIV epidemic.

Administered under the skin and absorbed slowly, Yeztugo requires a negative HIV test before starting. While side effects like injection site reactions, headaches, and nausea were noted, the drug’s transformative potential overshadows these hurdles. As Daniel O’Day, Gilead’s CEO, put it, this innovation could redefine HIV prevention and bring us closer to a world without new infections.